Fanny Leenhardt

Dr. Fanny Leenhardt

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2020 in Vaccines
Verified
Journal Article
Open access
PDF file
FLFélicien Le Louedec
Félicien Le Louedec
FLFanny Leenhardt
Fanny Leenhardt
CMClémence Marin
Clémence Marin
ÉCétienne Chatelut
étienne Chatelut
AEAlexandre Evrard
Alexandre Evrard
Joseph CiccoliniJoseph Ciccolini
Joseph Ciccolini
Immune check-point inhibitors are drugs that are markedly different from other anticancer drugs because of their indirect mechanisms of antitumoral action and their apparently random effect in terms of efficacy and toxicity. This marked pharmacodynamics variability in patients calls for reconsidering to what extent approved dosing used in clinical practice are optimal or whether they should require efforts for customization in outlier patients. To better understand whether or not dosing could be an actionable item in oncology, in this review, preclinical and clinical development of immune checkpoint inhibitors are described, particularly from the angle of dose finding studies. Other issues in connection with dosing issues are developed, such as the flat dosing alternative, the putative role therapeutic drug monitoring could play, the rise of combinatorial strategies, and pharmaco-economic aspects.

20 July 2021 in Cancers
Verified
Journal Article
Open access
PDF file
AMAlice Matheux
Alice Matheux
MGMatthieu Gassiot
Matthieu Gassiot
GFGaëlle Fromont
Gaëlle Fromont
FLFanny Leenhardt
Fanny Leenhardt
ABAbdelhay Boulahtouf
Abdelhay Boulahtouf
Philippe PourquierPhilippe Pourquier
Philippe Pourquier
Resistance to castration is a crucial issue in the treatment of metastatic prostate cancer. Kinase inhibitors (KIs) have been tested as potential alternatives, but none of them are approved yet. KIs are subject of extensive metabolism at both the hepatic and the tumor level. Here, we studied the role of PXR (Pregnane X Receptor), a master regulator of metabolism, in the resistance to KIs in a prostate cancer setting. We confirmed that PXR is expressed in prostate tumors and is more frequently detected in advanced forms of the disease. We showed that stable expression of PXR in 22Rv1 prostate cancer cells conferred a resistance to dasatinib and a higher sensitivity to erlotinib, dabrafenib, and afatinib. Higher sensitivity to afatinib was due to a ~ 2-fold increase in its intracellular accumulation and involved the SLC16A1 transporter as its pharmacological inhibition by BAY-8002 suppressed sensitization of 22Rv1 cells to afatinib and was accompanied with reduced intracellular concentration of the drug. We found that PXR could bind to the SLC16A1 promoter and induced its transcription in the presence of PXR agonists. Together, our results suggest that PXR could be a biomarker of response to kinase inhibitors in castration-resistant prostate cancers.

11 April 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
FLFanny Leenhardt
Fanny Leenhardt
FFFrederic FITENI
Frederic FITENI
LGLudovic Gauthier
Ludovic Gauthier
MAMarie Alexandre
Marie Alexandre
SGSéverine GUIU
Séverine GUIU
William JacotWilliam Jacot
William Jacot
Palbociclib is a good candidate for therapeutic drug monitoring (TDM) due to its narrow therapeutic range and frequency of toxicities, particularly high-grade neutropenia. In this prospective, bicentric clinical trial, we evaluated the palbociclib exposure–toxicity relationship and determined the relevant sources of palbociclib pharmacokinetic variability, including drug–drug interactions (DDI). We followed 58 patients (mean age: 62.9 years) for 1 year. The geometric median of palbociclib plasma trough concentration (Ctrough) was 74.1 ng/mL. Neutropenia occurred in 70.7% of patients (high grade in 67.2% of patients). High-grade neutropenia occurrence during the first two palbociclib cycles was higher in patients with lower neutrophil count at initiation (p = 0.002). Palbociclib plasma Ctrough was correlated with high-grade neutropenia occurrence during the first two cycles (p = 0.024, OR 5.51). Co-treatment with agents that may interfere with palbociclib PK significantly influenced palbociclib Ctrough (p < 0.05). CYP3A4/P-glycoprotein inhibitors increased by 25% palbociclib Ctrough (p = 0.035), while antacids reduced it by 20% (p = 0.036). However, DDI did not have any significant effect on high-grade neutropenia occurrence (p > 0.05). This study confirms the major role of TDM to manage palbociclib safe use from the first week of treatment, particularly the significant incidence of hematological toxicity. Moreover, this first dedicated prospective study confirmed the importance of characterizing co-treatments to limit the DDI risk with oral-targeted therapies.

1 September 2020 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
FLFanny Leenhardt
Fanny Leenhardt
MGMatthieu Gracia
Matthieu Gracia
CPCatherine Perrin
Catherine Perrin
CMClaudia Muracciole-Bich
Claudia Muracciole-Bich
BMBénédicte Marion
Bénédicte Marion
AEAlexandre Evrard
Alexandre Evrard

20 July 2021 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
FLFanny Leenhardt
Fanny Leenhardt
MAMarie Alexandre
Marie Alexandre
SGSeverine Guiu
Severine Guiu
SPStephane Pouderoux
Stephane Pouderoux
MBMelanie Beaujouin
Melanie Beaujouin
WJWilliam Jacot
William Jacot

1 September 2021 in Annales Pharmaceutiques Françaises
Verified
Journal Article
Closed access
LRL. Rubira
L. Rubira
FLFanny Leenhardt
Fanny Leenhardt
CPC. Perrier
C. Perrier
FPF. Pinguet
F. Pinguet